Iomai, GlaxoSmithKline, Novartis, U.S. Department of Health and Human Services infectious news

HHS awarded $132.5 million to three companies to develop adjuvant-based vaccines and adjuvants for H5N1 avian influenza. GSK will receive $63.3 million over five years for vaccine R&D, and the U.S. government also may opt to fund an additional $44 million of related programs. GSK said its lead adjuvanted pandemic vaccine is in registration in Europe and will enter a U.S. Phase I/II trial next quarter.

NVS will receive $54.8 million over five years to develop its MF59 adjuvant in a cell culture-based pandemic influenza vaccine and to support the establishment of a U.S.-based MF59 production facility. ...